News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Cipla has a robust governance model focused on sustainability
Subscribe To Our Newsletter & Stay Updated
